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Abstract
DUX4 (Double Homeobox Protein 4) is a nuclear transcription factor encoded at each D4Z4 unit of a tandem-repeat array at
human chromosome 4q35. DUX4 constitutes a major candidate pathogenic protein for facioscapulohumeral muscular
dystrophy (FSHD), the third most common form of inherited myopathy. A low-level expression of DUX4 compromises cell
differentiation in myoblasts and its overexpression induces apoptosis in cultured cells and living organisms. In this work we
explore potential molecular determinants of DUX4 mediating nuclear import and cell toxicity. Deletion of the hypothetical
monopartite nuclear localization sequences RRRR23, RRKR98 and RRAR148 (i.e. NLS1, NLS2 and NLS3, respectively) only
partially delocalizes DUX4 from the cell nuclei. Nuclear entrance guided by NLS1, NLS2 and NLS3 does not follow the
classical nuclear import pathway mediated by a/b importins. NLS and homeodomain mutants from DUX4 are dramatically
less cell-toxic than the wild type molecule, independently of their subcellular localization. A triple DNLS1-2-3 deletion
mutant is still partially localized in the nuclei, indicating that additional sequences in DUX4 contribute to nuclear import.
Deletion of $111 amino acids from the C-terminal of DUX4, on a DNLS1-2-3 background, almost completely re-localizes
DUX4 to the cytoplasm, indicating that the C-ter tail contributes to subcellular trafficking of DUX4. Also, C-terminal deletion
mutants of DUX4 on a NLS wild type background are less toxic than wild type DUX4. Results reported here indicate that
DUX4 possesses redundant mechanisms to assure nuclear entrance and that its various transcription-factor associated
domains play an essential role in cell toxicity.
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Introduction
DUX4 is double-homeodomain transcription factor encoded at
the tandem repeat D4Z4 (i.e. FSHD1 locus) on the human
chromosomal region 4q35 [1,2]. D4Z4 repeats belong to a family
of human 3.3 kb repeats dispersed through the genome [3,4].
Shortening of the 4q35-linked D4Z4 tandem repeat [5] is
associated with the prevalent form of facioscapulohumeral
muscular dystrophy (FSHD, OMIM 158900), the third most
common form of inherited myopathy in humans [6]. FSHD1
patients have 1–10 D4Z4 repeat units whereas non-affected
individuals have 11–100 D4Z4 repeats [7,8]. Pathogenic short
D4Z4 alleles are hypomethylated and associated with a 4q
polymorphic variant called 4qA [9,10]. FSHD2 patients, who do
not have D4Z4 contractions at 4q35, have also decreased DNA
methylation at the 4q35 D4Z4-tandem repeat [11].
DUX4 is a nuclear protein endogenously transcribed in
myoblasts from FSHD patients [12]. Cultured myoblasts or
myotubes from affected individuals express the DUX4 protein in a
very limited number of nuclei [13]. The protein is highly expressed
in germinal cells in testis [13] and also in cultured pluripotent stem
cells derived from fibroblast [13]. The DUX4 gene is turned off
when cultured pluripotent cells are differentiating [13]. Transgene
expression of DUX4 in various cultured transfected cells leads to
apoptosis [12] and its expression in myoblasts disrupts the normal
myogenic regulatory pathway [14], alters normal myotube
morphology [14,15] and increases stress susceptibility [14].
Expression of DUX4 in mice muscles causes a TP53-dependent
myopathy, which is dependent on the integrity of its homeodo-
mains [16]. It has been shown that DUX4 homeodomains bind
the canonical binding site TAAT [17,18] and activate the
expression of PITX1, a gene specifically up-regulated in tissues
from FSHD patients [17]. The potential pathogenic role for
DUX4 in FSHD [12,19] is supported by elegant molecular and
genetics studies showing that a stable DUX4 mRNA is transcribed
from the distal D4Z4 unit in pathological FSHD alleles [20].
In this work we show that DUX4 has multiple domains driving
nuclear import and that its various transcription-factor domains
participate in DUX4-mediated cell death. Our results indicate that
DUX4 possesses redundant mechanisms to assure nuclear
entrance and its transcription factor activity may play a role in
FSHD pathogenesis.
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Results
Three Monopartite NLS Contribute to Nuclear Sorting of
DUX4
Visual and in silico (i.e. PSORT II software; http://psort.nibb.
ac.jp) inspection of the primary sequence of DUX4 showed the
existence of two potential monopartite NLSs: NLS1 (RRRR23)
and NLS2 (RRKR98), located at the N-terminus portion of
homeodomains 1 and 2, respectively (Fig. 1) (see Ref. [21]). A less
conserved core of basic amino acids (NLS3: RRAR148) is present
at the C-terminus portion of homeodomain 2 (Fig. 1). The core of
basic amino acids at this NLS3 is not conserved in homeodomain
1 (Fig. 1). NLS3 was considered a potential NLS sequence because
it matches the consensus (R/K)(R/K)X(R/K), including a C-
terminal histidine residue (i.e. RRARH149) present in the
epidermal growth factor receptor ERB3 (i.e. RRRRH), from the
EGFR protein family [22].
Site directed mutagenesis was used to prepare single, double
and triple DNLS deletion mutants of DUX4, lacking the cluster of
basic amino acids corresponding to NLS1, NLS2 and/or NLS3
(see Materials and Methods section). To analyze their subcellular
location, these DUX4 DNLS mutants were expressed in transient
transfection experiments using the promoter and enhancer
sequences from the CMV (i.e. pcDNA3.1, Invitrogen). To exclude
potential artifacts dependent on the massive cell death caused by
DUX4 [12], these experiments were performed using short times
of transfection (i.e. 24 hr) (see Materials and Methods section). In
these studies, transfected HepG2 (Fig. 2A) and HeLa (not shown)
cells were immunostained using the anti-DUX4 monoclonal
antibody Mab9A12 [17]. Western blot analyses of total protein
extracts from these transfected cells indicated that all the DUX4
DNLS mutants were properly expressed (Fig. 2B). Figure 2A shows
that wild type DUX4 completely localizes to the cellular nuclei
[12]. A marked delocalization of DUX4 from nuclei was observed
in the triple mutant DNLS1-2-3 (Fig. 2A). Partial nuclear
delocalization was also observed for the double mutant DNLS1-
2 and, to a lesser extent, for the double mutants DNLS1-3 and
DNLS2-3. A faint cytoplasmic staining of DUX4 was observed for
the single mutants DNLS1 and DNLS2, suggesting only minor
delocalization from nuclei. The single mutant DNLS3 mostly
localize at the cell nuclei suggesting that it has a minor role in
nuclear entrance (Fig. 2A). A quantitative analyses of the
subcellular distribution of the various DUX4 NLS mutants is
shown in Figure 2C.
Taken together these results indicate that all the analyzed NLSs
partially contribute to nuclear entrance, being their apparent
relative driving force for nuclear import of DUX4:
NLS1=NLS2.NLS3.
We hypothesized that the DNLS1-2-3 mutant still partially
localizes to the nuclei because a fraction of DUX4, which is a
relatively small molecule (i.e. 50 kDa), may enter the nuclei by
passive diffusion [21]. To study this possibility we prepared a
fusion of wild type DUX4 to GFP, rendering a large chimeric
protein of about 80 kDa (see Materials and Methods section),
considered unable to enter the nuclei by passive diffusion [23,24].
This wild type DUX4-GFP fusion completely localizes to the
nuclei (not shown). Also, this fused protein conserves the toxic
Figure 1. Conceptual DUX4 amino acid sequence. Homeodo-
mains 1 (residues 19 to 79) and 2 (residues 94 to 149) are underlined.
NLS1 (RRRR23), NLS2 (RRKR98) and NLS3 (RRAR148) are indicated (boxes).
IWF1 (IWF65) and IWF2 (IWF140) are also indicated (ovals). The positions
of the C-terminal amino acids remaining at the various C-terminal
deletion mutants is shown.
doi:10.1371/journal.pone.0075614.g001
Figure 2. Subcellular distribution of DUX4 DNLS mutants. (A)
DUX4 wild type (WT) as well as deletion mutants (DNLS1, DNLS2, DNLS3,
DNLS1-2, DNLS1-3, DNLS2-3 and DNLS1-2-3) were expressed in HepG2
cells and immunotsained using the monoclonal mAb9A12 antibody.
Non background staining was observed when cells were transfected
with the empty pcDNA3.1 vector (not shown; see Material and Methods
section). (B) Western blot analysis of DUX4 wild type and NLS mutants
showed in Fig. 2A, transiently expressed (i.e. 24 hs) in HepG2 cells. Cells
transfected with an empty vector are shown (vector). The Western blot
was developed using mAb9A12. The position of molecular weight
markers (i.e. 72.8, 47.8 and 33.9 kDa) is indicated. (C) Percentage of
nuclear-located DUX4 wild type and NLS mutants as determined by
measuring the relative nuclear: cytoplasm fluorescence in HepG2
transfected cells (see Fig. 2A). Data are expressed as mean6SD of two
independent experiments. The symbols (**) and (*) indicate significant
difference vs. DUX4 wt, p,0.01 and p,0.05, respectively. For details,
see text.
doi:10.1371/journal.pone.0075614.g002
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properties of native wild type DUX4 (see below), indicating that
fusion of GFP at the C-terminus of DUX4 does not alter the
molecular structure of DUX4 determinants of cell toxicity.
Fusions of DUX4 DNLS mutants to GFP (see Materials and
Methods section) were constructed using a modified DUX4 gene
carrying a short deletion of 53 amino acids at the C-terminus (see
Fig. 1). This DUX4 DC53 protein is much less toxic than DUX4
wild type (see below) and does not disturb nuclear localization of
DUX4 (Fig. 3e). All the fusions to GFP have the expected
molecular weight as determined in Western blots developed with a
monoclonal antibody against GFP (see below and Materials and
Methods section). The DNLS-GFP gene fusions have a subcellular
distribution (Fig. 3a to 3d) similar to that observed using the
immunostaining approach (Fig. 2A and 2C).
Nuclear Entrance of DUX4 is not Mediated by a/b
Importins
Proteins carrying monopartite K(K/R)X(K/R) or bipartite (K/
R)(K/R)X10–12(K/R)3/5 (corresponding (K/R)3/5 to at least
three of five consecutive lysines or arginines) NLSs [25,26] are
imported into the nucleus via the a/b importins pathway [27,28].
To study the possibility that NLS1, NLS2 and/or NLS3 transport
the DUX4 cargo via a/b importins, we used an experimental
strategy based on two recently described nuclear import peptide
inhibitors of the a/b importins pathway [29]. These peptides,
designed bimax1 and bimax2, bind tightly to a-importin,
independently of b-importin, inhibiting the release of the cargo
into the nucleus and probably sequestering the a/b-importins into
this subcellular compartment [29]. The reporter cytoplasmic
protein GUS fused to GFP (i.e. GUS-GFP), as well as a derivative
construct containing the NLS from the large antigen T from the
virus SV40 (PKKKRKV) (i.e. GUS-GFP-NLS; see Materials and
Methods), were used as a control to validate these studies. Fig. 4A
shows that GUS-GFP is a cytoplasmic protein which localizes to
the nuclei when carrying the NLSSV40. Co-transfection of GUS-
GFP-NLS with plasmid pGrx1 (i.e. expressing Grx1, a potential
competitive cargo; see Materials and Methods section) does not
delocalize GUS-GFP-NLS from the nuclei. Thus, co-expression of
a cargo containing a bonafide NLS does not delocalize GUS-GFP-
NLS [29]. Co-transfection of GUS-GFP-NLS with a plasmid
expressing bimax1 or bimax 2, however, completely inhibits the
nuclear entrance of GUS-GFP-NLS (Fig. 4A). These results
validate the use of the bimax peptides to test the functional
dependence of DUX4 NLS1, NLS2 and NLS3 on the a/b-
importins pathway. Each NLS from DUX4 (i.e. NLS1+, NLS2+
and NLS3+) was independently tested in the corresponding double
mutant background (i.e. NLS1+, NLS2+ and NLS3+ were tested
in DNLS2-3, DNLS1-3 and DNLS1-2 double mutants, respec-
tively). GFP gene fusions of each double mutant were constructed
using a modified DUX4 gene carrying a deletion of 205 amino
acids from the C-terminus (Fig. 1; see Materials and Methods
section). This C-terminal region partially contributes to DUX4
nuclear sorting (see below) and may contain a cryptic NLS,
potentially covering the results of the bimax peptides inhibition
assay. Also, this DUX4-DC205 protein is much less toxic than
DUX4 wild type (see below) and does not disturb nuclear
localization (see Fig. 3j). In these studies, NLS1+, NLS2+ and
NLS3+ were insensitive to inhibition of the a/b-importins
pathway mediated by peptide bimax 1 (see Fig. 4B) or bimax2
(not shown). These experiments indicate that nuclear import of
DUX4 mediated by NLS1, NLS2 and NLS3 does not follow the
classical nuclear import pathway of a/b-importins. Dependence
on the a/b-importins pathway of a potential cryptic NLS present
at the C-terminus of DUX4 (see below) was tested using the
DNLS1-2-3 triple mutant with a wild type C-terminus fused to
GFP (see Materials and Methods section). Nuclear import of this
protein was not inhibited by the bimax peptides (Fig. 4Bj and 4Bo).
Amino Acids IWF from DUX4 Homeodomains do not
Contribute to Nuclear Location
The IWF sequence is a well conserved motif in homeodomains
[30]. This motif is located at the third helix of the homeobox,
which participates in protein-nucleic acid and protein-protein
interactions [31]. It has been shown that transcription factor
TTF1 localizes to the cell nuclei only when it maintains intact its
NLS (RRKRR) and its IWF motif [32]. Nuclear import of TTF1
via the NLS and nuclear retention through binding to nucleic acids
via the IWF both appear to contribute to nuclear location of TTF1
[32]. To explore the possibility that IWF sequences from DUX4
homeodomains 1 and/or 2 contribute to nuclear location, and/or
nuclear retention of a leaked fraction of DUX4 into the nucleus,
we prepared deletion mutants DIWF1 (IWF65) and DIWF2
Figure 3. Subcellular distribution of DNLS mutants fused to GFP. DUX4 mutants DC53 and DC205, lacking 53 (a to e) or 205 (f to j) amino acid
residues from the C-terminus, were used as templates to introduce the double deletions DNLS1-2 (a and f), DNLS1-3 (b and g) and DNLS2-3 (c and h),
or the triple deletion DNLS1-2-3 (d and i). Mutants DC53 and DC205 on a NLS+ background are also shown (e and j, respectively). All constructs were
fused to GFP and expressed in HepG2 cells. Magnifications are 20X (a to d and f to i) and 40X (e and j). For details, see text.
doi:10.1371/journal.pone.0075614.g003
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(IWF140). Combined deletion mutants of IWF1, IWF2 and the
DUX4 DNLSs described above were also prepared (see Materials
and Methods section). Cells were transfected with these various
mutants and immunostained using the anti-DUX4 monoclonal
antibody mAb9A12. Figure 5 shows that single DIWF1 and
DIWF2 mutants, as well as the double mutant DIWF1-2,
completely localize to the nuclei. Combined DIWF and DNLS
mutants have a subcellular localization that follows the pattern of
the corresponding single or combined DNLS mutants (compare
images from Fig. 5 with Fig. 2A and Fig. 3).
We conclude from these studies that the IWF motifs from
homeodomains 1 and 2 do not participate in either nuclear
location or nuclear retention of DUX4.
The C-terminal Tail of DUX4 Participates in Nuclear
Import
Results presented above suggest that additional sequences in
DUX4 mediate its subcellular trafficking to the nuclei. The
potential contribution of the C-terminal region of DUX4 in
nuclear sorting was studied using a series of deletion derivatives
lacking 50, 53, 86, 111, 180 and 205 amino acids from its C-
terminus (see Fig. 1 and Materials and Methods section). To study
the role of the C-terminus in nuclear import independently from
the contribution of NLS1, NLS2 and NLS3, all the DC mutants
were prepared in a triple mutant DNLS1-2-3 background.
Mutants DC50, DC53, DC86, DC111, DC180 and DC205 were
fused to GFP and their subcellular localization was analysed in
transiently transfected cells. The DC-GFP fusion proteins have the
expected molecular weight according to Western blots analyses
using a monoclonal antibody against GFP (Fig. 6A). Figure 6B
shows the quantitative analysis of the nuclei/cytoplasm distribu-
tion of the DC mutants. As it was shown above, the triple DNLS1-
2-3 mutant largely delocalizes from the nuclei (Fig. 6B; see also
Fig. 2A). Mutants DC50, DC53 and DC86 (see Materials and
Methods section) behave similarly to DNLS1-2-3 (Fig. 6B, C-WT),
indicating that deletion of a large portion of the C-terminus (i.e.
50, 53 or 86 amino acids) does not modify the nuclear location of
DUX4. Mutants DC111, DC180 and DC205, however, almost
completely delocalize from the nuclei (Fig. 6B).
Taken together, these results indicate that the C-terminus of
DUX4 contributes, independently of the NLSs, to nuclear location
of this protein. The domain contributing to nuclear entrance
appears to be located around amino acids 314 to 338 (see Fig. 1).
We also analyzed the subcellular distribution of a short and large
deletion of the C-terminus (i.e. mutants DC53 and DC205) in a
wild type NLS+ background. These mutants completely localize to
the nuclei (Fig. 3, e and j, respectively), suggesting that the
monopartite NLS1, NLS2, NLS3 and the C-terminus region
around amino acids 314 to 338 constitute independent pathways
for DUX4 nuclear entrance (see Discussion). Extensive in silico
analyses of the region around amino acids 314 to 338 did not show
clues on the molecular nature of a potential NLS at this region.
Alternatively, DUX4 may constitute a cargo for a homologous or
heterologous specifically interacting protein driving DUX4 to the
cell nuclei. Perhaps, endogenous expressed DUX4 and/or DUX-
like proteins may form heteromeric molecules driving transfected
DUX4 into the nucleus.
The finding that the C-terminus region of DUX4 contributes to
nuclear entrance offers a potential sensitive strategy to test the
differential driving force of the above characterized DUX4
monopartite NLSs. With this aim, we studied GFP-labelled
DNLS1, DNLS2 and DNLS3 deletion mutants on the C-terminal
deletion background DC205. It is assumed that, on this
background, sequences NLS1, NLS2 and NLS3 are the only
contributing sequences for nuclear import of DUX4. Figure 3
Figure 4. Nuclear entrance of DUX4 is not mediated by a/b importins. (A) Transiently transfected GUS-GFP (bacterial b-glucuronidase) is a
cytoplasmic protein (a) that is imported into nuclei when carrying the NLS from SV40 (GUS-GFP-NLS; see b). Co-transfection of GUS-GFP-NLS with a
competitive cargo (Grx, yeast glutaredoxin) does not alter its nuclear import (c). Co-transfection with plasmids expressing peptides bimax1 (d) or
bimax2 (e) blocks nuclear import of GUS-GFP-NLS. (B) GFP fusions of DUX4 wild type (f and k) or mutants DNLS1-2 (g and l), DNLS1-3 (h and m),
DNLS2-3 (i and n), DNLS1-2-3 (j and o) were co-transfected with the control plasmid expressing the competitive cargo Grx (f to j) or a plasmid
expressing bimax 1 (k to o). Nuclear entrance of DUX4 wild type or mutants was insensitive to the bimax 1 peptide. Similar results were obtained
using the bimax 2 (not shown).
doi:10.1371/journal.pone.0075614.g004
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shows that mutant DNLS1-2 only partially delocalizes from nuclei
in a DC53 background (3a), is much more delocalized on a DC205
background (3f). A similar nuclear delocalization was obtained for
the double mutants DNLS1-3 and DNLS2-3 (Fig. 3, compare b
with g and c with h). Nuclear delocalization was less notorious for
the mutant DNLS2-3. These results support the contention that
the C-terminal domain contributes to the nuclear sorting of
DUX4. Also, they confirm that NLS1 and NLS2 are the more
relevant NLS recognized in DUX4.
DUX4-mediated Cell Death Depends on the Integrity of
the Homeodomains and the C-terminal Region
DUX4 is a transcription factor [17,33,34] and its normal role
requires its homeodomains and the transcriptional enhancer
activity associated to its C-terminus [17,33]. To study these
aspects, in a first step we explored if the various characterized
DUX4 DNLS mutants have different degrees of toxicity. In these
experiments we used a co-transfection strategy previously
described [12]. This experimental approach uses co-transfection
of a tester plasmid expressing GFP with a second testing plasmid
expressing DUX4. The mass ratio tester: testing DNA used for the
co-transfecting plasmids was adjusted in a way that most of the
cells transfected with the tester plasmid (i.e. expressing GFP) are
co-transfected with the testing plasmid (see Materials and Methods
section) being the observed number of positive GFP cells inversely
related to the toxicity of the testing plasmid [12]. Quantitative
determination of the percentage of GFP positive cells allows to
measure the degree of toxicity of the various DUX4 mutants
analyzed. In these studies, duplicated independent experiments
were analyzed at 48 and 72 hr following co-transfection. Figure 7
shows that control transfection experiments (i.e. the tester plasmid
expressing GFP together with the empty testing vector) have a
high number (,50%) of GFP-positive cells at 48 and 72 hr (a and
f, respectively; see also Fig. 8). A very low number of GFP-positive
cells was observed when the wild type version of DUX4 was tested
(b and g), consistent with our original demonstration that DUX4 is
a toxic protein and causes cell death when expressed in cultured
cells [12]. A dramatic decrease in cell toxicity was observed when
cells were transfected with DNLS1, DNLS2 and DNLS1-2 mutants
(Fig. 7), being the double mutant DNLS1-2 less toxic that the
single mutants DNLS1 and DNLS2 (e and j). Thus, even when
these DNLS mutants are mostly localized into the nuclei, like wild
type DUX4, its toxic effect is dramatically lower. Fig. 8 shows that
single mutants DNLS1 and DNLS2 have 14% and 21%,
respectively, of the toxicity of the wild type DUX4 (see Materials
and Methods section) while the double and triple mutants (i.e.
DNLS1-2 and DNLS1-2-3) have 9% and 4%, respectively. On the
other hand, the single mutant DNLS3 has 56% of the DUX4 wild
type toxicity (Fig. 8).
Even when the toxicity of the DNLS mutants correlates with
their relative presence in the nucleus (i.e.
WT.NLS3.NLS2=NLS1.NLS1-2.NLS1-2-3), it is remark-
able that mutants that are still highly concentrated in the nuclei,
like the single mutants DNLS1 and DNLS2, as well as the double
mutant DNLS1-2, have a low degree of toxicity. These results
suggest that DUX4-toxicity is, at least in part, mediated by protein
domains that include the NLS sequences. To further explore this
idea we incorporated into the various DNLS mutants the strong
NLS from the T-antigen of virus SV40 (see Materials and
Methods section). Transient transfection with these DNLS-
NLSSV40 constructs and immunostaining of DUX4 confirmed
that NLSSV40 completely re-drives the various DNLS mutants to
the nuclei (not shown). Analyses of toxicity of these DUX4 DNLS-
NLSSV40 mutants show the same degree of toxicity that the
corresponding DNLS mutant, irrespective of the presence of
NLSSV40 (not shown). Thus, the decrease of toxicity of the various
DUX4 DNLS mutants is not associated with lower nuclear import.
Considering that the NLS1 and NLS2 sequences are located
within the homeodomains (Fig. 1), we explored if homedomain
mutants (see Fig. 5) have any effect on cell toxicity. In these studies,
single DIWF1 and DIWF2 mutants, as well as combinations of
DIWF and DNLS mutants, were explored using the GFP co-
transfection toxicity assay described above. Figure 9 shows that
single DIWF mutants are about 40–50% less toxic than the wild
type while combinations of the DIWF with DNLS mutants have a
level of toxicity similar to the corresponding DNLS mutant. These
results suggest that the diminished toxicity of DIWF and DNLS
mutants is based on the alteration of the same molecular
determinant of toxicity, perhaps the homeodomains themselves
Figure 5. The IWF motif does not contribute to nuclear location of DUX4. Single deletion mutants DIWF1 (a) and DIWF2 (e), the double
mutant DIWF1-2 (d), as well as combined deletion mutants DIWF1-DNLS1 (b), DIWF2-DNLS2 (f), DIWF1-DNLS1-2 (c), DIWF2-DNLS1-2 (g) and DIWF1-2-
DNLS1-2 (h), were transiently transfected (i.e. 24 hr) into HepG2 and immunostained using the anti-DUX4 monoclonal antibody mAb9A12 (see
Materials and Methods section). The single and double DIWF mutants completely localize to the nuclei. Combined DIWF-DNLS mutants localize
following the pattern observed for the corresponding DNLS mutants. For details, see text.
doi:10.1371/journal.pone.0075614.g005
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(see Discussion). Supporting this idea, the double mutant DIWF1-2
has the lowest level of toxicity, suggesting that both homeodomains
independently contribute to the toxic effect of DUX4. In a
separate group of experiments we analyzed the contribution of the
C-terminal region of DUX4 to cell toxicity. C-terminal deletion
mutants DC53 and DC205 were fused to GFP and used to
transiently transfect HepG2 cells (see Materials and Methods
section). The percentage of GFP+ cells observed 24 and 48 hr
after transfection was scored as an approximate measure of
DUX4-mediated cell toxicity. Both C-terminal mutants DC53 and
DC205 were dramatically less toxic than the wild type protein
fused to GFP (not shown).
Discussion
DUX4 is a nuclear, endogenously expressed protein [13]. Low-
level expression of DUX4 compromises cell differentiation in
myoblasts [14] while its overexpression induces apoptosis in
cultured cells [12], a phenomenon which appears to involve p53
activity [16]. DUX4-mediated cell death is a ubiquitous phenom-
enon occurring in many cell types and living organisms [14,19].
The finding that DUX4 mRNA is stably expressed in myoblasts
only from pathogenic FSHD haplotypes [20] supported its
potential pathogenic role in FSHD [17,20,35,36]. Stabilization
of the DUX4 transcript is mediated by a poly(A) signal present
only at permissive pathological FSHD alleles [20]. It is unknown
Figure 6. Subcellular trafficking of DUX4 C-terminal deletion mutants. (A) Western blot analysis of GFP fusions of DUX4 wild type (DUX4-
GFP), DNLS1-2-3 triple deletion mutant (NLS1-2-3) as well as C-terminus deletion mutants DC50, DC53, DC86, DC111, DC180 and DC205 transiently
expressed (i.e. 24 hs) in HepG2 cells. All the C-terminus deletion mutants are in a DNLS1-2-3 mutant background. The Western blot was developed
using a monoclonal anti-GFP antibody. The position of molecular weight markers (i.e. 101.3, 72.8, 47.8 and 33.9 kDa) is indicated). (B) Quantitative
analyses of the cytoplasmic distribution of DUX4 C-terminal deletion mutants. HepG2 cells were transfected with plasmids expressing GFP fusions of
the triple DNLS1-2-3 mutant having either a wild type (C-WT) or different deleted (DC50, DC53, DC86, DC111, DC180 and DC205) C-terminal domains.
The percentage of cytoplasmic green fluorescence was determined as indicated in Material and Methods section. Experiments were performed in
blind experiments by counting 20 fluorescent cells from three randomly selected microscope fields. Data are expressed as mean6SD of two
independent experiments. The symbol (*) indicates significant difference vs. DUX4 wild type (C-WT) (p,0.05).
doi:10.1371/journal.pone.0075614.g006
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why high level expression of DUX4 in testes is not toxic [13].
Perhaps the normal function of DUX4 is associated with the co-
expression of a tissue-specific, constitutive or developmentally-
regulated protein that blocks or bypasses its toxic effect.
DUX4 is a transcription factor evolutionarily conserved in
several species [4,17,33,34]. The normal function of DUX4 may
require nuclear entrance as well as the integrity of its homeodo-
mains and its acidic C-terminal tail [37,38]. The N-terminal ends
of DUX4 homeodomains have been considered responsible for
subcellular trafficking of DUX4 to the nuclei [21]. Nuclear sorting
of proteins depends on NLSs, generally consisting of clusters of
basic amino acids [39]. Model monopartite and bipartite
sequences are represented by the NLS from the large T antigen
of virus SV40 (PKKKRKV132) [25] and the NLS from
nucleoplasmin (KRPAATKKAGQAKKKK170) [26], respective-
ly. In this work we determined that DUX4 sequences NLS1 and
NLS2, at the N-terminal ends of the homeodomains, only partially
contribute to nuclear entrance. Mutagenesis and deletion analyses
indicate that additional sequences (i.e. NLS3) as well as the C-
terminal domain of DUX4 contribute to nuclear sorting.
Functional redundancy was observed for the various DUX4
NLSs: single NLS mutants only partially delocalize from nuclei.
Loss of nuclear localization was more important for the double
(DNLS1-2, DNLS1-3, DNLS2-3) and triple (DNLS1-2-3) mutants.
The existence of additional molecular determinants of nuclear
entrance in DUX4 was indicated from the fact that the triple
DNLS1-2-3 mutant still partially localizes in nuclei. Analyses of
various C-terminus deletion derivates of DUX4, in a mutant
background DNLS1-2-3, indicated that a short C-terminal
sequence, around amino acids 314 and 338, participates in
DUX4 nuclear entrance. Thus, multiple protein domains from
DUX4 contribute to subcellular trafficking of this protein.
Protein containing classic NLSs are imported to the nucleus by
a heteromeric protein complex composed of importin a and
importin b [27,28]. In this work we used the peptides called
‘‘bimax’’, powerful inhibitors of the nuclear import pathway [29],
to explore if the various NLS recognized in DUX4 enter the nuclei
using the a/b importin pathway. Validation of the experimental
strategy was performed using a GUS-based reporter protein
containing NLSSV40. An independent molecular analysis of each
DUX4 NLS showed that none of these sequences drives the
protein to the nuclei via the a/b importin pathway.
Homeodomains are formed by three a-helices and a flexible N-
terminal arm [40,41]. The third helix, also known as the
Figure 7. Cell toxicity of DUX4 DNLS mutants. A plasmid expressing GFP was co-transfected for 48 (a to e) or 72 (f to j) hours with an empty
vector (a and f) or plasmids expressing wild type DUX4 (b and g) or mutants DNLS1 (c and h), DNLS2 (d and i) and DNLS1-2 (e and j). About 70–80% of
green fluorescent cells were observed when a plasmid expressing GFP was co-transfecetd with an empty vector (i.e. a and f). DUX4-mediated cell
death, on the other hand, leaves a very low number of positive fluorescent cells (b and g) [12–19]. A marked reduction in toxicity was observed when
using DUX4 mutants DNLS1, DNLS2 and DNLS1-2. For details see text and Materials and Methods section.
doi:10.1371/journal.pone.0075614.g007
Figure 8. Cell toxicity of DUX4 DNLS mutants. The percentage of GFP positive cells was determined in co-transfection experiments at 24 (dark
gray) or 48 (light gray) hours post-transfection (see Materials and Methods section). Scoring was determined in blind experiments by counting 1000–
1500 cells (i.e. DAPI staining) from three randomly selected microscope fields. Data are expressed as mean6SD of two independent experiments. The
symbols (**) and (*) indicate significant difference vs. DUX4 wt, p,0.01 and p,0.05, respectively.
doi:10.1371/journal.pone.0075614.g008
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recognition helix, specifically interacts with the major groove of
DNA, while the N-terminal arm interacts with the minor groove
[42]. Key amino acids at these regions are IWF and Q‘‘50’’ [30,43].
In this work we studied the contribution of DUX4 homeodomains
to both subcellular traffic and toxicity of DUX4. Single deletion of
DUX4 IWF1 and IWF2 sequences, as well as a double deletion
IWF1-IWF2, does not affect the subcellular location of DUX4.
Thus, loss of IWF sequences, potentially determining DUX4
binding [17] to DNA and/or retention of DUX4 at the nuclei
[32], does not modify DUX4 nuclear location. The IWF mutants
have a marked reduction of DUX4 toxicity similar to that
observed for the various DUX4 DNLSs mutants. NLS1 and NLS2
mutants were also less toxic when carrying the sequence NLSSV40
which completely re-drives these mutants to the nuclei. Thus, the
low toxicity of DUX4 DNLS mutants would be explained because
NLS1 and NLS2 partially overlap, or are immediately adjacent, to
the nuclei acid binding region of DUX4 [44]. It is known that
basic amino acids from the N-terminus of homeodomains directly
interact with the DNA-minor groove [30,42] and disruption of
these sequences may affect the DNA-binding activity of DUX4
and/or its activity as a transcription factor. Less toxic variants of
DUX4 were also obtained when deleting the C-terminal region of
the protein. This C-terminal domain of DUX4 has the signature of
a transcription factor and differs from the non-toxic DUX4 highly
homologous protein DUX4c [34].
Results presented in this work suggest that DUX4 mediates its
toxic effect by: 1) the binding of DUX4 to physiological and/or
non-physiological target(s) via both homeodomains [17], and 2)
recruiting additional molecules via its C-terminus as a transcription
factor [33]. DUX4 expressed in myoblasts may compete for
specific target binding sites and cofactors participating in myotube
differentiation to disrupt a normal progression of this pathway (see
Ref. [14]). Overexpression of DUX4 in various cultured cell
models and organisms may lead to apoptosis via a non-
physiological pathway dependent on aberrant higher cellular
amounts of DUX4.
Shortening of the 4q35 region associated to FSHD and
characterization of the D4Z4 repetitive unit were published in
1993 and 1994, respectively [1,5]. DUX4 has emerged as the most
attractive candidate pathogenic protein in FSHD [20,35,36].
Studies directed towards an understanding of the normal
biological role of DUX4 as well as its molecular connection with
the pathophysiology underlying FSHD are in progress. Results
reported here are relevant to the biology of DUX4 and could have
an immediate impact on the basic knowledge and potential
pathogenic role of DUX4 in FSHD, as well as on the future
rational therapeutic approaches to cure FSHD.
Materials and Methods
DNA Manipulations
A vector expressing the DUX4 gene was constructed by
subcloning a 1.517 bp EagI/KpnI fragment, obtained from plasmid
pGEM/42 [12], into the NotI/KpnI sites of pcDNA3.1 (Invitrogen).
DNLS mutants were generated using the procedure described on
the QuikChangeH II Site-Directed Mutagenesis kit (Stratagene) as
follows: methylated template plasmid DNA was purified from E.
coli XL1-Blue (dam+). Reaction conditions for mutagenesis were
1.0 mM MgCl2, 2.0 mM of each dNTP, 125 ng of each reverse
and forward primers, 20 ng of template DNA and 2.5 U of Pfx
polymerase (Invitrogene) using a final volume of 50 ul. DNA was
denatured during 30 seconds at 94uC and PCR was performed
using 16 cycles of 30 seconds at 94uC, 1 min at 55uC and 7 min at
68uC. PCR products were digested with DpnI to eliminate the
methylated template DNA and used to transform competent XL1-
Blue. Primers used for mutagenesis are shown in Table 1. The
NLS from the T-antigen of virus SV40 (NLSSV40) was introduced
at the N-terminus of DUX4 DNLS mutants by directional cloning.
Briefly: a double-stranded oligonucleotide encoding a start codon
(ATG) followed by the NLSSV40 (PKKKRKV) (see Table 1) was
digested with XbaI and XhoI and cloned directionally into the XbaI
and XhoI sites present at the 59 of DUX4. All the mutant
constructions were verified by DNA sequencing.
GFP Gene Fusions
Plasmid pEGFP-N1 (Clontech, Palo Alto, CA) was used to clone
EGFP at the C-terminus of the various DUX4 mutants. Fusions to
wild type DUX4 and to deletions mutants DNLS1-2-3, DC180,
DC111, DC87 and DC50 were prepared by subcloning into
pEGFP-N1 the corresponding fragments obtained by PCR from
the various mutants prepared in plasmid pcDNA3.1. PCR
reactions contained a universal forward primer (UNI-F; Table 1),
having the DUX4 start codon (ATG), and a specific reverse
primer (see table 1). PCR products were digested with NheI
(restriction site on primer UNI-F) and KpnI (restriction site on the
reverse primer) and cloned directionally into pEGFP-N1. Gene
fusions to GFP on backgrounds DC205 or DC54 were prepared as
follows: plasmid DNA from mutants DNLS1, DNLS2, DNLS3,
Figure 9. Cell toxicity of DIWF mutants. The percentage of GFP positive cells was determined in co-transfection experiments at 24 (dark gray) or
48 (light gray) hours post-transfection (see Materials and Methods section). Scoring was determined in blind experiments by counting 1000–1500 cells
(i.e. DAPI staining) from three randomly selected microscope fields. Data are expressed as mean6SD of two independent experiments. The symbols
(**) and (*) indicate significant difference vs. DUX4 wt, p,0.01 and p,0.05, respectively.
doi:10.1371/journal.pone.0075614.g009
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DNLS1-2, DNLS1-3, DNLS2-3 and DNLS1-2-3 was first digested
with XhoI followed by partial digestion with PstI. DNA fragments
of 682 bp and 1.180 bp, corresponding to DC205 and DC53,
respectively, were purified from agarose gels and subcloned in-
frame at the N-terminus of GFP using sites XhoI and PstI from
pEGFP-N1. All constructs were verified by DNA sequencing.
Cell Culture and Cell Transfection
The subcellular distribution of DUX4 mutants was analyzed
using transiently transfected HepG2 (human hepatic carcinoma;
ATCC HB8065) and HeLa cells. In these studies, cells were grown
to 80–90% of confluence in RPMI 1640 plus 10% (v/v) fetal
bovine serum and appropriate supplements and transfected using
Lipofectamine 2000 (Invitrogen). Endogenous expression of
DUX4 was not detected in these cells. Immunocytochemical
staining was performed using anti-DUX4 monoclonal antibodies
Mab9A12 [17]. Transfected cells were washed three times with
PBS and then fixed in 4% paraformaldehyde/sucrose for 25 min
at room temperature. Cells were permeabilized with methanol,
15 min at 220uC, followed by 5 min at room temperature. After
incubation with PBS/5% BSA for 45 min the cells were incubated
at 4uC overnight with the primary antibody diluted 1:40 in PBS/
1% BSA. The next day, cells were washed three times with PBS
and incubated with the secondary antibody. Slides were mounted
using FluorSave (Calbiochem, La Jolla, CA) and fluorescence
images were captured under a Zeiss Axioplan-2 fluorescence
microscope. Quantitative determination of the distribution of
DUX4 at the nuclei and cytoplasm subcellular compartments was
performed using the ImageJ software and digital images of DUX4
transfected cells immunostained with the monoclonal antibody
Mab9A12 (see Fig. 2a and 2b).
Western Blot Analysis
Transfected cells were also analyzed by Western blot. Cells were
harvested in RIPA-DOC buffer (150 mM NaCl, 1% Triton X-
100, 1% Na-deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.2)
supplemented with a cocktail of protease inhibitors (SIGMA,
Catalogue number P8340). Cell lysates were clarified by centri-
fugation and extracted proteins boiled in Laemmli’s buffer for
10 min. After electrophoresis on 12% SDS-PAGE proteins were
electroblotted into PVDF filters (PolyScreen) using a TransBlot cell
(BioRad). Membranes were blocked in 5% nonfat dry milk in
TBST (20 mM Tris-HCl, pH 7.5; 150 mM NaCl, 0.1% Tween
20) at 4uC overnight and subsequently incubated with the primary
antibody at 4uC diluted in 1% nonfat dry milk – TBST. After
three washings with TBST, membranes were incubated with anti-
mouse IgG (diluted 1:20000) coupled with infrared dyes
(IRDye700 and IRDye800). Blots were scanned using Odyssey
Infrared Imager (LI-COR Biosciences, UK).
bimax 1 and Bimax 2 Peptides
The use of bimax 1 and 2 peptides was performed as described
[29]. Briefly: HepG2 cells were co-transfected with 300 ng of
plasmid bimax 1, bimax 2 (not shown) or pGRX1 (i.e. expressing
the nuclear protein Grx1) [29] and 700 ng of either GUS-GFP,
GUS-GFP-NLSSV40, double mutants DNLS1-2, DNLS1-3 or
DNLS2-3 fused to GFP in a DC205 background, DUX4 wild
type or DNLS1-2-3, fused to GFP using 1.5 ul of lipofectamine
2000 (Invitrogen) as specified by the manufacturer. Subcellular
distribution of green fluorescence was determined under the
microscope.
Cell Toxicity Assays
The effect of the DNLS and DIWF mutations on the DUX4-
mediated cell death was studied using a GFP-based co-transfection
assay previously developed in our laboratory [12]. Briefly, HepG2
cells were co-transfected with 150 ng of pEGFP-N1 and 350 ng of
the various analyzed constructs or the empty pcDNA3.1(+) vector
(500 ng total DNA) using 0.75 ul of Lipofectamine 2000
(Invitrogen) as specified by the manufacturer. The total amount
Table 1. Primers used for mutagenesis.
Name Sequence (59 to 39) Study
NLS1-F GAAGCCCGGGGACGAGGACTCGTTTGGACCC Deletion NLS1 (forward)
NLS1-R TCCTCGTCCCCGGGCTTCCGCGGGGAGGGTG Deletion NLS1 (reverse)
NLS2-F CGCGGCCCGCCAGAAGGCACCGCCGTCACCG Deletion NLS2 (forward)
NLS2-R GCCTTCTGGCGGGCCGCGTCTCCCGGGCCAG Deletion NLS2 (reverse)
NLS3-F GATTCAGATCTGGTTTCAGAATCACCCGGGACAG Deletion NLS3 (forward)
NLS3-R CTGTCCCGGGTGATTCTGAAACCAGATCTGAATC Deletion NLS3 (reverse)
H1IWF-F GAGCCCAGGGTCCAGCAGAATGAGAGGTCA Deletion IWF1 (forward)
H1IWF-R TGACCTCTCATTCTGCTGGACCCTGGGCTC Deletion IWF1 (reverse)
H2IWF-F GGAGTCCAGGATTCAGCAGAATCGAAGGGCCA Deletion IWF2 (forward)
H2IWF-R TGGCCCTTCGATTCTGCTGAATCCTGGACTCC Deletion IWF2 (reverse)
UNI-F TATGCTAGCCGATGGCCCTCCCGACACCCT GFP fusion (forward)
DUX4-R AAGGTACCATAAGCTCCTCCAGCAGAGCCC GFP fusion (reverse)
DC180-R AAGGTACCATCGGGGCGGCGTAGGCGAAATC GFP fusion (reverse)
DC112-R AAGGTACCATGCCCCAGCCCCACCACGGACTC GFP fusion (reverse)
DC88-R AAGGTACCATGGGCGCGGGCTGGGGAGGTG GFP fusion (reverse)
DC53-R AAGGTACCATCAGCAGCAGGCCGCAGGGGAGTG GFP fusion (reverse)
SV40-F ATTCTAGAGCCACCATGGCGCCGAAGAAGAAGCGGAAGGTCCTCGAGCG Cloning NLSSV40 (forward)
SV40-R CGCTCGAGGACCTTCCGCTTCTTCTTCGGCGCCATGGTGGCTCTAGAAT Cloning NLSSV40 (reverse)
doi:10.1371/journal.pone.0075614.t001
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of DNA used (500 ng) was in the linear range of response between
amounts of DNA and number of transfected cells. Duplicated
independent transfection and co-transfection experiments were
analyzed at 24 and 48 hours. The percentage of cells expressing
GFP was determined on random selected images obtained at the
fluorescence microscope. About 1,500–2,000 cells were examined
[i.e. positive DAPI (49,6-diamidino-2-phenylindole) staining].
Results were expressed as percentage of GFP positive cells 6 SD.
Statistical Analysis
Data in Figures 2C, 6B, 8 and 9 are expressed as mean6SD.
Statistical differences were determined by one-way ANOVA with
Dunnett’s post test using GraphPad InStat v.3.0 software.
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